Upstream Bio (UPB) Cash from Financing Activities (2023 - 2026)

Upstream Bio's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $598000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 1858.82% year-over-year to $598000.0 in Q1 2026; TTM through Mar 2026 was $3.1 million, a 99.25% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 99.42% from the prior year.
• Cash from Financing Activities eased to $598000.0 in Q1 2026 per UPB's latest filing, from $1.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $270.6 million in Q4 2024 and bottomed at -$1.6 million in Q3 2024.
• The 4-year median for Cash from Financing Activities is $686000.0 (2025), against an average of $42.2 million.
• Across the five-year window, Cash from Financing Activities surged 203594.74% in 2024 and slumped 100.36% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$133000.0 in 2023, then jumped by 203594.74% to $270.6 million in 2024, then sank by 99.59% to $1.1 million in 2025, then tumbled by 45.78% to $598000.0 in 2026.
• Per Business Quant, the three latest UPB Cash from Financing Activities figures stand at $598000.0 (Q1 2026), $1.1 million (Q4 2025), and $760000.0 (Q3 2025).